β阻塞剂在心血管疾病连续体中的作用:来自亚太地区的基于Delphi调查的协作共识
Saumitra Ray1, Tiny Nair2, Jps Sawhney3
1Department of Cardiology, AMRI Hospital (S), West Bengal, Kolkata, India.
Current medical research and opinion
|September 11, 2023
概括
在关于治疗心血管疾病的β阻断剂 (β阻断剂) 的科学陈述上达成共识. 这证实了β抑制剂,特别是β1选择性药物在各种心脏病中具有临床益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝塔抑制剂在控制心血管疾病方面至关重要.
- 了解它们在疾病范围内的最佳使用是必不可少的.
研究的目的:
- 开发关于贝塔阻断剂在心血管疾病中的使用的科学陈述.
- 专注于比索普罗罗尔的作用,它是一种β1选择性阻断剂.
主要方法:
- 采用了德尔菲共识方法.
- 11名亚太地区的心脏病专家参加了两轮调查.
- 需要达成共识>70%对36个陈述的同意.
主要成果:
- 在第一轮的大部分陈述中达成共识.
- 在第二轮之后,最终一组36份声明被批准.
- 这些声明涵盖高血压,心力衰竭,冠状动脉疾病和安全.
结论:
- 高度的共识证实了β抑制剂的临床益处.
- 选择性β1抑制剂对心血管疾病特别有益.
- 这些声明提供了关于使用β-阻断剂的指导.
更多相关视频
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
886
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
886
Heart Failure Drugs: β-Blockers
363
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
363
Adrenergic Antagonists: ɑ and β-Receptor Blockers
511
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
511
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
657
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
657
Antihypertensive Drugs: Types of β-Blockers
732
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
732
Antihypertensive Drugs: Action of β1 Blockers
476
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
476


